Erasca closed an upsized public offering, selling 25,875,000 shares at $10 per share to raise approximately $258.8 million in gross proceeds. The clinical‑stage precision oncology company said the financing included full exercise of the underwriters’ option and will fund ongoing development across its RAS/MAPK pathway programs. Erasca’s raise signals continued investor interest in targeted oncology platforms despite broader market volatility. The capital infusion is intended to support multiple clinical programs and extend cash runway ahead of key data readouts; it also highlights the active public financing window for select clinical‑stage biotechs.